337 related articles for article (PubMed ID: 36229710)
1. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
2. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
3. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
4. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
Downton T; Zhou F; Segara D; Jeselsohn R; Lim E
Drug Des Devel Ther; 2022; 16():2933-2948. PubMed ID: 36081610
[TBL] [Abstract][Full Text] [Related]
5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
6. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
Bhatia N; Hazra S; Thareja S
Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Scott JS; Barlaam B
Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
[TBL] [Abstract][Full Text] [Related]
8. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
9. Design of SERENA-6, a phase III switching trial of camizestrant in
Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
11. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
12. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
Zhou F; Yang G; Xue L; Liu Y; Guo Y; Zhu J; Yuan L; Gu P; Tang F; Shan J; Tang R
Breast Cancer Res; 2023 Aug; 25(1):96. PubMed ID: 37580832
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
15. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
16. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Hernando C; Ortega-Morillo B; Tapia M; Moragón S; Martínez MT; Eroles P; Garrido-Cano I; Adam-Artigues A; Lluch A; Bermejo B; Cejalvo JM
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360578
[TBL] [Abstract][Full Text] [Related]
17. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti C; De Angelis C; Bianchini G; Malorni L; Giuliano M; Hamilton E; Jeselsohn R; Jhaveri K; Curigliano G; Criscitiello C
Cancer Treat Rev; 2023 Jun; 117():102569. PubMed ID: 37146385
[TBL] [Abstract][Full Text] [Related]
18. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment.
Garcia-Fructuoso I; Gomez-Bravo R; Schettini F
Curr Opin Oncol; 2022 Nov; 34(6):635-642. PubMed ID: 36000362
[TBL] [Abstract][Full Text] [Related]
19. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.
Rugo HS
Clin Adv Hematol Oncol; 2023 Dec; 21(12):623-632. PubMed ID: 38039056
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]